Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

After the benchmark S&P/ASX 200 surged 7.5 per cent in 2024, investors are looking to see where the growth will come from in ...

The advent of a Trump presidency is accelerating a divergence on digital currencies between the world’s two largest economies ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip cashed in on major ...

Other stars in December included Orthocell (ASX:OCC), which was up 67% amid “outstanding” clinical trial results and expected ...

Aubiotech hopes to score some quick runs with a pre-budget submission on ways to fix the sector's "stubborn issues" ...

Kalamazoo Resources led materials sector gainers this morning as the release of drill assays from its Mallina West gold ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a ...

Morningstar’s analyst picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.

With pending news flow of significance coming in 2025, these ASX-listed gas companies could be worth putting on your radar.

ASX 200 edges up on a tech rally, while miners struggle, Barrick Gold threatens a Mali shutdown, and Bitcoin bounces back.